🚀 VC round data is live in beta, check it out!
Verrica Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Verrica Pharmaceuticals and similar public comparables like Pyxis Oncology, Laboratorios Richmond, Bioton, Vistin Pharma and more.
Verrica Pharmaceuticals Overview
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
Founded
2013
HQ
Employees
71
Website
Sectors
Financials (LTM)
EV
$72M
Verrica Pharmaceuticals Financials
Verrica Pharmaceuticals reported last 12-month revenue of $33M.
In the same LTM period, Verrica Pharmaceuticals generated $29M in gross profit and had net loss of ($22M).
Revenue (LTM)
Verrica Pharmaceuticals P&L
In the most recent fiscal year, Verrica Pharmaceuticals reported revenue of $36M and EBITDA of ($9M).
Verrica Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $33M | XXX | $36M | XXX | XXX | XXX |
| Gross Profit | $29M | XXX | $32M | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | 90% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($9M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (26%) | XXX | XXX | XXX |
| EBIT Margin | (49%) | XXX | (31%) | XXX | XXX | XXX |
| Net Profit | ($22M) | XXX | ($18M) | XXX | XXX | XXX |
| Net Margin | (66%) | XXX | (50%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Verrica Pharmaceuticals Stock Performance
Verrica Pharmaceuticals has current market cap of $100M, and enterprise value of $72M.
Market Cap Evolution
Verrica Pharmaceuticals' stock price is $5.83.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $72M | $100M | -0.1% | XXX | XXX | XXX | $-1.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVerrica Pharmaceuticals Valuation Multiples
Verrica Pharmaceuticals trades at 2.2x EV/Revenue multiple, and (7.6x) EV/EBITDA.
EV / Revenue (LTM)
Verrica Pharmaceuticals Financial Valuation Multiples
As of April 11, 2026, Verrica Pharmaceuticals has market cap of $100M and EV of $72M.
Equity research analysts estimate Verrica Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Verrica Pharmaceuticals has a P/E ratio of (4.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $100M | XXX | $100M | XXX | XXX | XXX |
| EV (current) | $72M | XXX | $72M | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (7.6x) | XXX | XXX | XXX |
| EV/EBIT | (4.5x) | XXX | (6.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.4x | XXX | 2.2x | XXX | XXX | XXX |
| P/E | (4.6x) | XXX | (5.6x) | XXX | XXX | XXX |
| EV/FCF | (3.6x) | XXX | (4.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Verrica Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Verrica Pharmaceuticals Margins & Growth Rates
Verrica Pharmaceuticals' revenue in the last 12 month declined by (7%).
Verrica Pharmaceuticals' revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.6M for the same period.
Verrica Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (7%) | XXX | (30%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (26%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (86%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 30% | XXX | 25% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 124% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verrica Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Pyxis Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Laboratorios Richmond | XXX | XXX | XXX | XXX | XXX | XXX |
| Bioton | XXX | XXX | XXX | XXX | XXX | XXX |
| Vistin Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| SynAct Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Verrica Pharmaceuticals M&A Activity
Verrica Pharmaceuticals acquired XXX companies to date.
Last acquisition by Verrica Pharmaceuticals was on XXXXXXXX, XXXXX. Verrica Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Verrica Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVerrica Pharmaceuticals Investment Activity
Verrica Pharmaceuticals invested in XXX companies to date.
Verrica Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Verrica Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Verrica Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Verrica Pharmaceuticals
| When was Verrica Pharmaceuticals founded? | Verrica Pharmaceuticals was founded in 2013. |
| Where is Verrica Pharmaceuticals headquartered? | Verrica Pharmaceuticals is headquartered in United States. |
| How many employees does Verrica Pharmaceuticals have? | As of today, Verrica Pharmaceuticals has over 71 employees. |
| Who is the CEO of Verrica Pharmaceuticals? | Verrica Pharmaceuticals' CEO is Jayson Rieger. |
| Is Verrica Pharmaceuticals publicly listed? | Yes, Verrica Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Verrica Pharmaceuticals? | Verrica Pharmaceuticals trades under VRCA ticker. |
| When did Verrica Pharmaceuticals go public? | Verrica Pharmaceuticals went public in 2018. |
| Who are competitors of Verrica Pharmaceuticals? | Verrica Pharmaceuticals main competitors are Pyxis Oncology, Laboratorios Richmond, Bioton, Vistin Pharma. |
| What is the current market cap of Verrica Pharmaceuticals? | Verrica Pharmaceuticals' current market cap is $100M. |
| What is the current revenue of Verrica Pharmaceuticals? | Verrica Pharmaceuticals' last 12 months revenue is $33M. |
| What is the current revenue growth of Verrica Pharmaceuticals? | Verrica Pharmaceuticals revenue growth (NTM/LTM) is (7%). |
| What is the current EV/Revenue multiple of Verrica Pharmaceuticals? | Current revenue multiple of Verrica Pharmaceuticals is 2.2x. |
| Is Verrica Pharmaceuticals profitable? | No, Verrica Pharmaceuticals is not profitable. |
| What is the current net income of Verrica Pharmaceuticals? | Verrica Pharmaceuticals' last 12 months net income is ($22M). |
| What is the current FCF of Verrica Pharmaceuticals? | Verrica Pharmaceuticals' last 12 months FCF is ($20M). |
| What is Verrica Pharmaceuticals' FCF margin? | Verrica Pharmaceuticals' last 12 months FCF margin is (60%). |
| What is the current EV/FCF multiple of Verrica Pharmaceuticals? | Current FCF multiple of Verrica Pharmaceuticals is (3.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.